Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form prior to any study-specific evaluation Be ≥18 yrs of age at the time the informed consent form is signed Be either AR-directed therapy-naive or have received 1-2 lines of AR-directed therapy in the castration-resistant setting. Adequate organ function ECOG 0 or 1 Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM) Have disease progression after initiation of most recent therapy
Exclusion Criteria:
Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer Have received greater than 2 previous lines of chemotherapy for mCRPC Prior treatment with any PARP inhibitor Symptomatic and/or untreated central nervous system metastases Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug Spinal cord compression, symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks Any clinically significant cardiovascular disease Taking any concomitant medications or herbs that could interfere or interact with the study drug
